Perspectives in oncology drug pricing - Reply

Daniel A. Goldstein*, David H. Howard, Christopher R. Flowers

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)402
Number of pages1
JournalJAMA Oncology
Volume2
Issue number3
DOIs
StatePublished - 1 Mar 2016
Externally publishedYes

Funding

FundersFunder number
Infinity Pharmaceuticals
National Institutes of Health, Abbvie, Acerta, Celgene
Pfizer
Gilead Sciences
Spectrum Pharmaceuticals
Onyx Pharmaceuticals
Janssen Pharmaceuticals

    Cite this